Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21980158 | 0.84 | EGLN1 (0.31) | TP53 | |
| SCHEMBL21980122 | 0.83 | GPR119 (0.46) | SMN1; SMN2THRBMAPTKDM4EDPP4 | |
| SCHEMBL21980179 | 0.81 | GPR119 (0.46) | SMN1; SMN2THRBMAPTKDM4EDPP4 | |
| SCHEMBL25939333 | 0.79 | THRB (0.53) | SMN1; SMN2THRBMAPTKDM4EDPP4 | |
| SCHEMBL21979953 | 0.78 | TRPV3 (0.54) | SMN1; SMN2THRBMAPTKDM4EDPP4 | |
| SCHEMBL23290764 | 0.78 | MAPT (0.43) | SMN1; SMN2THRBMAPTKDM4EDPP4 | |
| SCHEMBL26664217 | 0.78 | SMN1; SMN2 (0.49) | SMN1; SMN2THRBMAPTKDM4EDPP4 | |
| SCHEMBL14157519 | 0.78 | SMN1; SMN2 (0.47) | SMN1; SMN2THRBMAPTKDM4EDPP4 | |
| SCHEMBL30672544 | 0.78 | KDM4E (0.46) | SMN1; SMN2THRBMAPTKDM4EDPP4 | |
| SCHEMBL26664417 | 0.78 | KDM4E (0.46) | SMN1; SMN2THRBMAPTKDM4EDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384789-B2 | Compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-3634953-B1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-4151627-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| US-20220251098-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2022-08-11 | — | — | US | disclosed |
| US-11407753-B2 | Compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-20220151938-A1 | TABLET FOR USE IN TREATING HUNTINGTON'S DISEASE AND METHOD OF MAKING THE SAME | PTC THERAPEUTICS, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-20200165256-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220151938-A1 | TABLET FOR USE IN TREATING HUNTINGTON'S DISEASE AND METHOD OF MAKING THE SAME | HTT, HYPK, ATXN2 | SMN1; SMN2 51/4885THRB 1337/4885MAPT 19/4885 |
| US-20220251098-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, FH | SMN1; SMN2 104/4885THRB 2497/4885MAPT 15/4885 |
| US-20200165256-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, FH | SMN1; SMN2 104/4885THRB 2497/4885MAPT 15/4885 |
| US-11407753-B2 | Compounds for treating Huntington's disease | HTT, HYPK, FH | SMN1; SMN2 104/4885THRB 2497/4885MAPT 15/4885 |
| US-12384789-B2 | Compounds for treating Huntington's disease | HTT, HYPK, FH | SMN1; SMN2 104/4885THRB 2497/4885MAPT 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.